Actinium Pharmaceuticals Inc (ATNM) Stock Price, Quote & News

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle c...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 677 3870

Website: www.actiniumpharma.com

Address:

100 Park Avenue, 23rd Floor, New York, United States

gooddoggie Jul. 25 at 11:53 PM

$ATNM Everything is going according to plan.

0 · Reply

johnny4cures Jul. 25 at 8:37 PM

$ATNM ⭐ 3. HERTHENA alone cannot protect Merck HERTHENA is an ADC. ADC resistance is inevitable. HERTHENA will produce: HER3‑high salvage CDCP1‑high salvage MDSC‑rich salvage hypoxic salvage metastatic salvage HERTHENA cannot kill these populations. ATNM‑400 can. Actimab‑A amplifies ATNM‑400 by clearing MDSCs. So Merck needs: ✔ HERTHENA → to map HER3 ✔ ATNM‑400 → to kill HER3/CDCP1 salvage ✔ Actimab‑A → to fix the tumor microenvironment This is the only complete HER3 strategy.

1 · Reply

johnny4cures Jul. 25 at 6:55 PM

$ATNM C says, "The Single Most Important Strategic Relationship HERTHENA was funded by Daiichi Sankyo and Merck (Merck & Co). This manuscript was funded by Daiichi Sankyo Company Limited and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. Employees of both companies had a role in the design and oversight of the study. (DOI) Merck funded the HERTHENA trial. Merck's scientists designed it. Merck's employees oversaw it. The trial that validates HER3 across 10 tumor types was co-funded by the company that is simultaneously the most motivated primary ATNM-400 acquirer — because Merck needs Actimab-A for Keytruda biosimilar defense. Merck knows exactly what HERTHENA showed. They co-funded it. They co-designed it. Their employees have seen the data before it is publicly presented. When Merck's BD team models ATNM-400's value, they incorporate HERTHENA data that the public has not yet seen — because they funded and oversaw the trial."

1 · Reply

johnny4cures Jul. 25 at 6:30 PM

$ATNM ⭐ Clean synthesis **HERTHENA‑PanTumor01 expands ATNM‑400 and Actimab‑A by mapping HER3 biology across many tumor types, generating HER3/CDCP1‑high resistance populations, validating HER3 as a multi‑tumor target, and providing free clinical signal‑finding data that Actinium can immediately exploit with superior alpha‑radioconjugate efficacy. HERTHENA is the signal‑finder. ATNM‑400 is the modality‑superior successor. Actimab‑A is the immune‑modulation backbone.**

0 · Reply

johnny4cures Jul. 25 at 6:26 PM

$ATNM ⭐ 6. HERTHENA provides clinical data Actinium can use without paying for it HERTHENA provides: safety profiles dosing windows HER3 expression thresholds biopsy‑based HER3 quantification metastatic distribution patterns HER3‑linked resistance mechanisms HER3 salvage population sizes All of this is free clinical intelligence for Actinium. HERTHENA is effectively de‑risking ATNM‑400’s entire multi‑tumor program.

0 · Reply

englishkaren Jul. 25 at 4:43 PM

$ATNM https://www.linkedin.com/pulse/fifth-weapon-oncology-paul-healy--yapie/

3 · Reply

johnny4cures Jul. 25 at 5:21 AM

$ATNM "Gastric/GEJ — 800,000 Global Annual Patients Globally gastric cancer kills more than 700,000 people annually. It is the fourth most common cancer globally. HER3 is expressed in 65–75% of gastric tumors. After trastuzumab resistance in HER2+ disease, HER3 upregulates as the bypass escape route. The global burden of gastric cancer — particularly in Asia where HER3-DXd's HERTHENA trial enrolls heavily in Japan, South Korea, and Taiwan — makes gastric cancer one of the highest-impact ATNM-400 indications globally if Orbis approval is achieved simultaneously."

0 · Reply

johnny4cures Jul. 25 at 5:19 AM

$ATNM " Pancreatic Cancer — The Hardest Cancer To Treat HER3 has been identified as a key survival pathway in metastatic CRC and PDAC. HER3-targeted therapies may be effective in treating patients with HER3-expressing CRC and PDAC, highlighting the importance of applying HER3 expression as a predictive biomarker. (nih) Pancreatic cancer kills approximately 95% of patients within 5 years. Median OS is 6–11 months with current best therapy. There is essentially no effective targeted therapy in the second-line setting. HER3 is expressed in 55–75% of PDAC tumors. KRAS inhibitor resistance — the most exciting development in PDAC — consistently activates HER3 bypass signaling. The KRAS → HER3 resistance pipeline creates 50,000 US PDAC patients annually who will have HER3-upregulated disease at progression. ATNM-400 in PDAC, combined with Actimab-A MDSC depletion — PDAC is the most MDSC-dense tumor type in oncology — is the most complete treatment strategy for the deadliest common cancer."

0 · Reply

johnny4cures Jul. 25 at 5:17 AM

$ATNM Cervical cancer showed 85.7% HER3-high at both initial and recurrent diagnosis — the highest and most stable HER3 expression of all gynecological cancers. This is the single highest baseline HER3 expression of any cancer type confirmed by primary source peer-reviewed data. 85.7% HER3-high means the Zr-89 PET scan in cervical cancer patients will be positive in virtually every patient. No patient selection uncertainty. Essentially universal target engagement. ATNM-400 in cervical cancer has the most confirmed, most stable, most universal target expression of any indication in the HERTHENA basket.

0 · Reply

johnny4cures Jul. 25 at 5:15 AM

$ATNM Ovarian Cancer — The Most Important HERTHENA Indication HER3-DXd has shown preclinical antitumor efficacy in HER3-expressing cancers. (PubMed Central) Ovarian cancer has 80% HER3 expression at recurrence. Platinum-resistant ovarian cancer has essentially no effective targeted therapy. MDSC suppression is the primary mechanism of ICI failure in ovarian cancer. ATNM-400 addresses ovarian cancer through alpha radiation killing HER3-expressing cells. Actimab-A addresses it simultaneously through MDSC depletion enabling immune response. Combined — as a triplet with a checkpoint inhibitor — this is the most mechanistically complete ovarian cancer combination ever designed.

0 · Reply

Actinium Pharmaceuticals Slides: Investor presentation

2026-06-03T13:39:19.000Z - 7 weeks ago

Actinium presented preclinical data on ATNM-400 in NSCLC at SNMMI 2026

Jun 3, 2026, 8:00 AM EDT - 7 weeks ago

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Jun 3, 2026, 7:25 AM EDT - 7 weeks ago

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models

2026-06-01T12:52:17.000Z - 7 weeks ago

Actinium Pharmaceuticals names Steffen Heeger MD, MSc as Chief Medical Officer

Jun 1, 2026, 8:00 AM EDT - 7 weeks ago

Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development

CNTA

2026-06-01T11:12:02.000Z - 7 weeks ago

Actinium Pharmaceuticals presents new radiochemistry data at SNMMI

Jun 1, 2026, 7:00 AM EDT - 7 weeks ago

Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates

2026-05-29T21:41:04.000Z - 2 months ago

Actinium Pharmaceuticals receives two patent allowances from CIPO

May 29, 2026, 5:31 PM EDT - 2 months ago

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

May 29, 2026, 5:30 PM EDT - 2 months ago

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

May 27, 2026, 9:00 AM EDT - 2 months ago

NorthStar and QSA Global Announce Multi-Year Strategic Partnership to Strengthen Actinium-225 Supply Chain for Targeted Alpha Therapies

May 15, 2026, 7:00 AM EDT - 2 months ago

Actinium Pharmaceuticals Slides: Investor presentation

May 8, 2026, 7:00 AM EDT - 2 months ago

Actinium Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 2 months ago

Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization

2026-04-22T11:29:41.000Z - 3 months ago

Actinium presents data from Actimab-A studies at AACR

2026-04-22T11:23:31.000Z - 3 months ago

Actinium presents preclinical results for ATNM-400 at AACR

Apr 22, 2026, 7:00 AM EDT - 3 months ago

Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting

Apr 22, 2026, 7:00 AM EDT - 3 months ago

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting

Apr 15, 2026, 8:00 AM EDT - 3 months ago

NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225

Apr 9, 2026, 7:00 AM EDT - 3 months ago

Actinium Pharmaceuticals Slides: Investor presentation

Apr 6, 2026, 7:30 AM EDT - 3 months ago

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

Mar 30, 2026, 7:00 AM EDT - 4 months ago

Actinium Pharmaceuticals Annual report: Q4 2025

Feb 17, 2026, 8:00 AM EST - 5 months ago

BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research

2025-12-12T13:50:27.000Z - 8 months ago

Actinium Pharmaceuticals presents new data on anti-tumor activity of ATNM-400

Dec 12, 2025, 8:45 AM EST - 8 months ago

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

2025-12-01T13:50:36.000Z - 8 months ago

Actinium Pharmaceuticals announces preclinical data for ATNM-400

Dec 1, 2025, 8:45 AM EST - 8 months ago

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

Nov 17, 2025, 8:30 AM EST - 8 months ago

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

NVS

Nov 14, 2025, 4:00 PM EST - 9 months ago

Actinium Pharmaceuticals Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 9 months ago

Actinium Pharmaceuticals Proxy statement: Proxy Filing

2025-10-27T11:15:51.000Z - 9 months ago

Actinium Pharmaceuticals’ ATNM-400 shows superior anti-tumor activity

AZN JNJ

Oct 27, 2025, 7:00 AM EDT - 9 months ago

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-10-24T12:35:37.000Z - 9 months ago

Actinium presents preclinical data for ATNM-400

Oct 24, 2025, 8:30 AM EDT - 9 months ago

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

2025-10-13T16:25:11.000Z - 10 months ago

Actinium Pharmaceuticals to announces preclinical data from ATNM-400 program

Oct 13, 2025, 12:10 PM EDT - 10 months ago

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 8:30 AM EDT - 10 months ago

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Aug 8, 2025, 7:00 AM EDT - 1 year ago

Actinium Pharmaceuticals Quarterly report: Q2 2025

2025-07-31T12:42:35.000Z - 1 year ago

Actinium Pharmaceuticals’ ATNM-400 shows improved survival in prostate cancer

Jul 31, 2025, 8:30 AM EDT - 1 year ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

2025-06-23T17:33:54.000Z - 1 year ago

Actinium highlights expanded data set for ATNM-400 in prostate cancer

Jun 23, 2025, 11:30 AM EDT - 1 year ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 12, 2025, 11:00 AM EDT - 1 year ago

Actinium Pharmaceuticals Transcript: Life Sciences Investor Forum

2025-05-20T12:31:41.000Z - 1 year ago

ATNM Lawsuit Alert! Class Action Lawsuit Against Actinium Pharmaceuticals

May 9, 2025, 12:00 AM EDT - 1 year ago

Actinium Pharmaceuticals Quarterly report: Q1 2025

2025-05-06T12:50:27.000Z - 1 year ago

Actinium enrolls first patient on the trial studying Iomab-ACT

May 6, 2025, 8:45 AM EDT - 1 year ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Apr 30, 2025, 7:25 AM EDT - 1 year ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

2025-04-28T12:47:44.000Z - 1 year ago

Actinium Pharmaceuticals’ ATNM-400 shows efficacy in prostate cancer study

NVS

2025-04-28T12:13:37.000Z - 1 year ago

Actinium’s Actimab-A shows antileukemic activity in AML models

SNDX

Apr 10, 2025, 9:00 AM EDT - 1 year ago

Actinium Pharmaceuticals Transcript: 15th Annual LD Micro Invitational 2025

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Actinium Pharmaceuticals Annual report: Q4 2024

2025-03-25T19:20:49.000Z - 1 year ago

Actinium Pharmaceuticals enters supply pact with Eckert & Ziegler

gooddoggie Jul. 25 at 11:53 PM

$ATNM Everything is going according to plan.

0 · Reply

johnny4cures Jul. 25 at 8:37 PM

1 · Reply

johnny4cures Jul. 25 at 6:55 PM

1 · Reply

johnny4cures Jul. 25 at 6:30 PM

0 · Reply

johnny4cures Jul. 25 at 6:26 PM

0 · Reply

englishkaren Jul. 25 at 4:43 PM

$ATNM https://www.linkedin.com/pulse/fifth-weapon-oncology-paul-healy--yapie/

3 · Reply

johnny4cures Jul. 25 at 5:21 AM

0 · Reply

johnny4cures Jul. 25 at 5:19 AM

0 · Reply

johnny4cures Jul. 25 at 5:17 AM

0 · Reply

johnny4cures Jul. 25 at 5:15 AM

0 · Reply

johnny4cures Jul. 25 at 5:11 AM

$ATNM C this " Categorically Superior To HER3-DXd In Every HERTHENA Indication This is the critical insight. HER3-DXd is an investigational treatment and doctors are not able to prescribe it (Taylor & Francis Online) — but its data from HERTHENA-PanTumor01 is completing right now. When those results read out, they will show which indications have positive signals from HER3 targeting. Every indication where HER3-DXd ADC shows a positive signal, ATNM-400 alpha radioconjugate will show a superior signal. Here is precisely why for each indication:"

0 · Reply

Pinto72 Jul. 25 at 4:17 AM

$ATNM Just a friendly reminder…….. @johnny4skin claimed this would be trading at $800 per share, post Ad Hoc……….. Pre R/S🚀🚀🚀🚀🚀🚀🚀🚀 Trading at consistent ALL TIME LOWS is eXtReEmLeE bUlLiSh!!!!!🤣🤣🤣🤣🤣🤣🤣 AAVIE!!!!!!🤣🤣🤣🤣🤣🤣

0 · Reply

johnny4cures Jul. 25 at 4:04 AM

$ATNM The last 3 posts show this sequence for 10 different tumor types in the trial in which they create the future targets for atnm 400 ⭐ HERTHENA → ATNM‑400 Tumor‑by‑Tumor Sequence Map HER3‑DXd finds the signals; ATNM‑400 exploits the biology. This is the real strategic sequence across all 10 tumor types in HERTHENA‑PanTumor01.

1 · Reply

johnny4cures Jul. 25 at 3:56 AM

$ATNM • One of the few modalities that works in pancreatic cancer Sequence: HERTHENA signal → ATNM‑400 salvage → ATNM‑400 mid-l TUMOR TYPE 8 — Ovarian HERTHENA: • HER3 expression mapped • ADC resistance → HER3 ↑ ATNM‑400: • Alpha therapy kills platinum-resistant clones • Works post-ADC, post-PARP Sequence: HERTHENA signal → ATNM‑400 salvage TUMOR TYPE 9 — Endome HERTHENA: • HER3 expression confirmed • ADC resistance → HER3 ↑ + CDCP1 ↑ ATNM‑400: • Alpha therapy kills ICI-resistant clones • Works in metastatic endometrial disease Sequence: HERTHENA signal → ATNM‑400 salvage TUMOR TYPE 10 — Colorectal HERTHENA: • HER3 expression mapped • ADC resistance → HER3 ↑ ATNM‑400: • Alpha therapy kills KRAS-mutant CRC • Works in ADC-resistant salvage Sequence: HERTHENA signal → ATNM‑400 salvage → ATNM‑400 m

0 · Reply

johnny4cures Jul. 25 at 3:56 AM

$ATNM • Complements or surpasses Pluvicto id-line Sequence: HERTHENA signal → ATNM‑400 salvage → ATNM‑400 mid-line TUMOR TYPE 4 — Head & Neck (HER3-high) HERTHENA: • Shows HER3 expression • ADC resistance → HER3 ↑ + CDCP1 ↑ ATNM‑400: • Alpha therapy kills heterogeneous, hypoxic tumors • Ideal for post-ICI failure Sequence: HERTHENA signal → ATNM‑400 salvage TUMOR TYPE 5 — Esophageal HERTHENA: • HER3 expression confirmed • ADC resistance → HER3 ↑ ATNM‑400: • Alpha therapy kills deep, hypoxic cores • Works regardless of mutation status Sequence: HERTHENA signal → ATNM‑400 salvage TUMOR TYPE 6 — Gastric HERTHENA: • HER3 expression mapped • ADC resistance → HER3 ↑ + CDCP1 ↑ ATNM‑400: • Alpha therapy bypasses ADC limitations • Kills heterogeneous gastric tumors Sequence: HERTHENA signal → ATNM‑400 salvage TUMOR TYPE 7 — Pancreatic HERTHENA: • HER3 expression confirmed • ADC resistance → HER3 ↑ + CDCP1 ↑ ATNM‑400: • Alpha therapy kills hypoxic, stroma-rich tumors

0 · Reply

johnny4cures Jul. 25 at 3:56 AM

$ATNM TUMOR TYPE 1 — NSCLC (EGFR, KRAS, HER3-high) HERTHENA: • Shows HER3 expression in EGFR/KRAS tumors • Produces partial responses • Resistance → HER3 ↑ + CDCP1 ↑ ATNM‑400: • Follows with alpha radioconjugate • Kills EGFR/KRAS clones regardless of mutation • Kills ADC-resistant cells • Kills hypoxic cores Sequence: HERTHENA signal → ATNM‑400 salvage → ATNM‑400 mid-line → ATNM‑400 front TUMOR TYPE 2 — Breast (ER+/HER2-, HER2-low, ADC-failed) HERTHENA: • Shows HER3 expression in endocrine-resistant tumors • ADC resistance → HER3 ↑ + CDCP1 ↑ ATNM‑400: • Kills HER3/CDCP1-high salvage population • Kills ADC-resistant clones • Works post-Etcamah, post-Truqap, post-PARP Sequence: HERTHENA signal → ATNM‑400 salvage → ATNM‑400 mid-line → ATNM‑400 frontline TUMOR TYPE 3 — Prostate (PSMA-negative, HER3-high) HERTHENA: • Maps HER3 expression in PSMA-negative disease • ADC resistance → HER3 ↑ ATNM‑400: • Kills PSMA-negative tumors • Kills HER3/CDCP1-high clones

0 · Reply

gooddoggie Jul. 25 at 12:04 AM

$ATNM I’m checking in.

0 · Reply

Pinto72 Jul. 24 at 8:53 PM

$ATNM ATM = BANKRUPTCY🚀🚀🚀🚀🚀 HELLOOOOOOOOOO , DONNA!!!!!! eXtReEmLeE bUlLiSh!!!🤣🤣🤣🤣🤣🤣

0 · Reply

Pickerbefore Jul. 24 at 8:14 PM

$ATNM $28 million market cap. What a joke Seth! More cash on hand. The market hates the stock along with the pitiful management that just takes paychecks for dropping off the face of the Earth. Seth is the biggest moron on Earth.

0 · Reply

Slainte13579 Jul. 24 at 7:27 PM

$ATNM Fat lady is warming up….

0 · Reply

Lomond Jul. 24 at 5:10 PM

$ATNM they need to be looking for a new CEO

0 · Reply

biotrade123 Jul. 24 at 4:46 PM

$ATNM New 52W low.

0 · Reply

Market Cap	26.98M
Revenue (ttm)	90,000.00
Net Income (ttm)	-33.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-37,655.55%
Debt to Equity Ratio	0.00

Volume	113,300
Avg Vol	115,080
Day's Range	N/A - N/A
Shares Out	31.38M
Stochastic %K	0%
Beta	-0.02
Analysts	Strong Sell
Price Target	$5.00